M&A / Deals Autoimmune disease biotech Odyssey sets terms for $225m IPO PharmaphorumAfter abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.Immunology & InflammationRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaphorum After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year. Immunology & Inflammation Read full story Post navigation Previous: Cytospire hauls in $83M for a new type of T cell engagerNext: Latus Bio secures $97m in funding to boost gene therapy access Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
